Condition
Endometrial Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 233 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid TumorsNCT07814248 · 2026-09-02
RECRUITINGSL-28 for Advanced Solid TumoursNCT07341737 · 2026-08-14
RECRUITINGA Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsNCT07383506 · 2026-07-23
RECRUITINGA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11
RECRUITINGA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationsNCT07610798 · 2026-06-01
RECRUITINGStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsNCT07524322 · 2026-06-01
RECRUITINGTirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · 2026-04-27
RECRUITING18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · 2026-04-27
RECRUITINGENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese CohortNCT07808164 · 2026-03-19
RECRUITINGNavigation Intervention for Adolescent and Young Adult Cancer SurvivorsNCT07406087 · 2026-03-15
RECRUITING177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23
RECRUITINGDistance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11
RECRUITINGDosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialNCT07227077 · 2026-02-07
RECRUITINGEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619 · 2026-01-20
RECRUITINGEndoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial CancerNCT07397624 · 2026-01-08
RECRUITINGStudy Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsNCT07444814 · 2025-12-19
RECRUITINGAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsNCT07371663 · 2025-12-03
RECRUITINGA Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07
RECRUITINGA Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNCT07182149 · 2025-10-30
RECRUITINGA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsNCT07109726 · 2025-09-23
RECRUITINGDESTINY-PANTUMOUR04NCT07124000 · 2025-09-18
RECRUITINGA Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITINGA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid TumorNCT07612891 · 2025-07-04
RECRUITINGA Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasNCT06999187 · 2025-06-03
RECRUITINGA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITINGA Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · 2025-04-18
RECRUITINGPredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)NCT07327489 · 2025-04-14
RECRUITINGA Study of PHST001 in Advanced Solid TumorsNCT06840886 · 2025-03-31
RECRUITINGDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · 2025-03-27
RECRUITINGA Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic CancerNCT06738966 · 2025-03-10
RECRUITINGA Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845 · 2025-01-14
RECRUITINGA Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963 · 2025-01-07
RECRUITINGTrop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · 2024-12-23
RECRUITINGA Study of a Weight Loss Intervention in People With Endometrial CancerNCT06751589 · 2024-12-19
RECRUITINGA Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor AlphaNCT06547840 · 2024-09-03
RECRUITINGMolecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle FactorsNCT06680791 · 2024-07-15
RECRUITINGDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsNCT06239194 · 2024-06-12
RECRUITING177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962 · 2024-06-03
RECRUITINGA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesNCT06395519 · 2024-05-13
RECRUITINGEvaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast CancersNCT06800612 · 2024-03-22
RECRUITINGPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914 · 2024-03-22
RECRUITINGA Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470 · 2024-03-06
RECRUITINGA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26
RECRUITINGOpen Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsNCT06293898 · 2024-02-09
RECRUITINGONC201 and Atezolizumab in Obesity-Driven Endometrial CancerNCT05542407 · 2023-10-23
RECRUITINGRobotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial CancerNCT05974995 · 2023-09-01
RECRUITINGStudy of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30
RECRUITINGEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsNCT05983432 · 2023-08-08
RECRUITINGPhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168 · 2023-06-05
RECRUITINGA Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)NCT06028724 · 2023-05-26
RECRUITINGPhase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsNCT05856981 · 2023-04-03
RECRUITINGRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)NCT05579366 · 2022-12-07
RECRUITINGA Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · 2022-10-25
RECRUITINGStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06
RECRUITINGA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsNCT05377996 · 2022-08-15
RECRUITINGComprehensive Outcomes for After Cancer HealthNCT05349227 · 2022-06-23
RECRUITINGcfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseNCT05366881 · 2022-05-03
RECRUITINGAvera Cancer Sequencing and Analytics Protocol (ASAP)NCT05142033 · 2021-11-01
RECRUITINGA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482 · 2021-10-18
RECRUITINGA Beta-only IL-2 ImmunoTherapY StudyNCT05086692 · 2021-08-27
RECRUITINGCommon interventions
PembrolizumabDRUG16CarboplatinDRUG13PaclitaxelDRUG7DocetaxelDRUG5pembrolizumabBIOLOGICAL5BevacizumabDRUG4CisplatinDRUG4FulvestrantDRUG3GemcitabineDRUG3TirzepatideDRUG3AbemaciclibDRUG2atezolizumabDRUG2DurvalumabDRUG2Educational InterventionOTHER2NivolumabDRUG2OlaparibDRUG2ONC201DRUG2PemetrexedDRUG2quality-of-life assessmentPROCEDURE2Questionnaire AdministrationOTHER2RibociclibDRUG2RilvegostomigDRUG2TopotecanDRUG2TrastuzumabDRUG2Trastuzumab deruxtecanDRUG2
Leading sponsors
AstraZeneca
9
National Cancer Institute (NCI)
8
UNC Lineberger Comprehensive Cancer Center
5
Memorial Sloan Kettering Cancer Center
4
Case Comprehensive Cancer Center
3
Genmab
3
Incyte Corporation
3
Merck Sharp & Dohme LLC
3
NextCure, Inc.
3
Radiopharm Theranostics, Ltd
3
Alaunos Therapeutics
2
Alliance for Clinical Trials in Oncology
2
Centro di Riferimento Oncologico - Aviano
2
Elephas
2
Eli Lilly and Company
2
Trial status mix
COMPLETED77
RECRUITING66
ACTIVE_NOT_RECRUITING25
TERMINATED25
UNKNOWN21
NOT_YET_RECRUITING14
WITHDRAWN3
ENROLLING_BY_INVITATION1
SUSPENDED1
Phase mix
PHASE1115
PHASE267
NA39
PHASE39
EARLY_PHASE15
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.